Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ketanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.88 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.88 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.88 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.88 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.88 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.88 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketanserin SCHEMBL4142325 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 | |
| Ketanserin SCHEMBL29772991 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 | |
| Ketanserin SCHEMBL1651721 | 0.99 | CYP2D6 (1.00) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 | |
| Ketanserin SCHEMBL29361038 | 0.94 | HTR2A (1.00) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 | |
| Ketanserin SCHEMBL4862503 | 0.94 | HTR2A (1.00) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 | |
| Ketanserin SCHEMBL34294 | 0.94 | HTR2A (1.00) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 | |
| Ketanserin SCHEMBL1532014 | 0.93 | HTR2A (0.98) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 | |
| Ketanserin SCHEMBL2030457 | 0.93 | HTR2A (0.98) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 | |
| Ketanserin SCHEMBL30028921 | 0.93 | HTR2A (0.98) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 | |
| Altanserin SCHEMBL124037 | 0.91 | HTR2A (0.88) | CYP2D6CYP3A4HPGDALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112258-A1 | SEROTONIN RECEPTOR AS A TARGET FOR THERAPY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-05-30 | — | — | WO | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| CN-111405895-A | Controlled release pharmaceutical composition and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-07-10 | — | — | CN | claimed |
| CN-109157507-A | Ketanserin tartrate injection and preparation method thereof | 上海禾丰制药有限公司 | 2019-01-08 | — | — | CN | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20150290181-A1 | COMBINATION OF EFFECTIVE SUBSTANCES CAUSING SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF | VIVOZONE, INC. (KR) | 2015-10-15 | — | — | US | claimed |
| EP-2727473-A2 | COMBINATION OF EFFECTIVE SUBSTANCES CAUSING SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF | Vivozon, Inc. (KR) | 2014-05-07 | — | — | EP | claimed |
| WO-2011126937-A1 | TARGETED INTRACELLULAR DELIVERY OF OLIGONUCLEOTIDES VIA CONJUGATION WITH SMALL MOLECULE LIGANDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-10-13 | — | — | WO | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| WO-2004028548-A2 | INHIBITORS OF THE NITRIX OXIDE SYNTHASE III (NOS III) AS NEUROPROTECTIVE AGENTS | CARBOMER, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | claimed |
| EP-0522226-B1 | Eyedrop solution for the treatment of ocular hypertension containing ketauserin | COSTAGLIOLA CIRO (IT) | 1997-09-10 | — | — | EP | claimed |
| EP-0522226-A1 | Eyedrop solution for the treatment of ocular hypertension containing ketauserin | Costagliola, Ciro (IT) | 1993-01-13 | — | — | EP | claimed |
| EP-4724107-A2 | OPHTHALMIC FILMS | Fount Bio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-0335442-A2 | Agents for preserving or restoring the soundness of the skin | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-10-04 | — | — | EP | disclosed |
| EP-0268309-A2 | Serotonin antagonists for treating wounds | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | HTR2A 56/4885SLC6A3 277/4885ADRA2B 293/4885 |
| US-20040063612-A1 | Neuroprotective agents | GAP43, NLN, NOS3 | HTR2A 1077/4885SLC6A3 327/4885ADRA2B 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.